Glycogen storage disease type VIII (Concept Id: C0017927) An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present Glycogen Storage Disease Type VIII (GSD VIII Types of Glycogen Storage Disease. The main types of glycogen storage diseases in children are categorized by number and name. They include: Type I (Von Gierke disease) - this is the most common type of glycogen storage disease, and accounts for 90% of all glycogen storage disease cases; Type II (Pompe's disease, acid maltase deficiency Glycogen storage disease (GSD) is a rare condition that changes the way the body uses and stores glycogen, a form of sugar or glucose. Glycogen is a main source of energy for the body. Glycogen is stored in the liver. When the body needs more energy, certain proteins called enzymes break down glycogen into glucose
. GSD has two classes of cause: genetic and acquired Top 10 Types of Glycogen Storage Diseases. The following points highlight the top ten types of glycogen storage diseases. The types are: 1. von Gierke's Disease 2. Pompe's Disease 3. Amylopectinosis 4. MC Ardle's Disease 5. Galactosemia 6. Hereditary Fructose Intolerance 7. Lactosuria 8
Glycogen storage disease type 3 (GSDIII) is an inherited disorder caused by the buildup of glycogen in the body's cells.This buildup impairs the function of certain organs and tissues, especially the liver and muscles.Symptoms typically begin in infancy and may include hypoglycemia, hyperlipidemia (excess of fats in the blood), and elevated blood levels of liver enzymes; later symptoms may. Glycogen storage disease type 1 is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells.The accumulation of glycogen in certain organs and tissues, especially the liver, kidneys, and small intestines, impairs their ability to function normally.Researchers have described two types of glycogen storage disease type 1, which differ in their signs and. Glycogen storage disease (GSD) is the name for a group of disorders that interfere with the body's ability to make glycogen or convert glycogen into glucose. Depending on the type of GSD a child has, glycogen may build up in the liver, in the muscles, or both. GSD can also affect blood cells, the heart, kidneys, and other organs
.Because glycogen is an important source of energy, this can interfere with the normal functioning of muscle cells Glycogen storage disease type 13 (GSD13), also known as β-enolase deficiency, is an inherited disease of the muscles. The muscles of an affected individual are not able to produce enough energy to function properly, causing muscle weakness and pain Type I glycogen storage disease is associated with abnormalities in two genes. Mutations in the G6PC gene result in a deficiency in the glucose-6-phosphatase (G6Pase) enzyme and account for approximately 80% of GSDI. This type of GSDI is termed glycogen storage disease type Ia. Mutations in the SLC37A4 gene result in a deficiency in the glucose-6-phosphatase translocase enzyme (transporter. Glycogen storage disease type 2, also known as Pompe disease or acid maltase deficiency disease, is an inherited metabolic disorder. While glycogen storage disease type 2 is a single disease, it may be classified in 2 forms according to the rates of disease progression, its severity and the age at which symptoms start
Neutropenia and neutrophil dysfunction cause serious infections and inflammatory bowel disease in glycogen storage disease type Ib (GSD-Ib). Our discovery that accumulating 1,5-anhydroglucitol-6-phosphate (1,5AG6P) caused neutropenia in a glucose-6-phosphatase 3 (G6PC3)-deficient mouse model and in 2 rare diseases (GSD-Ib and G6PC3 deficiency) led us to repurpose the widely used antidiabetic. Glycogen storage disease type I. Abdominal sonogram showing large nodules in the liver. A child with glycogen storage disease type Ia. Glycogen storage disease type II. Photomicrograph of the liver. Note the intensively stained vacuoles in the hepatocytes (periodic acid-Schiff, original magnification X 27) Glycogen storage disease type 0, liver (liver GSD 0), a form of glycogen storage disease (GSD), is a rare abnormality of glycogen metabolism (how the body uses and stores glycogen, the storage form of glucose). Unlike other types of GSD, liver GSD 0 does not involve excessive or abnormal glycogen storage, and causes moderately decreased glycogen stores in the liver 1. Robert W. Marion, MD* 2. Esma Paljevic, PNP† 1. *Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY 2. †Pace University School of Nursing, Pleasantville, NY The glycogen storage diseases (GSDs) are a group of inherited metabolic disorders, each caused by deficiency of an enzyme involved in the production or breakdown of glycogen
Glycogen storage disease type IX (GSD-IX) is a group of at least four disorders characterized by a deficiency of the enzyme phosphorylase kinase. This enzyme is necessary to break down (metabolize) a type of complex sugar known as glycogen. Normally, glycogen is metabolized into a simple sugar known as glucose Glycogen storage disease type VI (GSD VI) is a type of glycogen storage disease caused by a deficiency in liver glycogen phosphorylase or other components of the associated phosphorylase cascade system. It is also known as Hers' disease, after Henri G. Hers, who characterized it in 1959. The scope of GSD VI now also includes glycogen storage disease type VIII, IX (caused by phosphorylase b. Glycogen storage disease type I. More than 80 mutations in the SLC37A4 gene have been found to cause glycogen storage disease type Ib (GSDIb). Most of these mutations change single protein building blocks (amino acids) in glucose 6-phosphate translocase
Glycogen storage disease type III. Approximately 100 mutations in the AGL gene have been found to cause glycogen storage disease type III (also called GSDIII or Cori disease). Most of these mutations lead to a premature stop signal in the instructions for making the glycogen debranching enzyme, resulting in a nonfunctional enzyme Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen. Glycogen storage diseases (GSDs) are inherited inborn errors of metabolism of carbohydrates. In general, these results from a lack of specific enzymes involved in the breakdown of amino acids or other metabolites, or the conversion of fat and carbohydrates to energy. This activity describes the evaluation and management of GSDs and explains the.
8 Glycogen storage disease type 0. Glycogen storage disease type 0 (OMIM 240600) is caused by a deficiency of the enzyme hepatic glycogen synthase . This enzyme is required for glycogen synthesis, and is encoded by the GYS2 gene on chromosome 12. Unlike other forms of glycogen storage disease, GSD type 0 does not involve the storage of. Glycogen Storage Disorders- Liver: Sequencing Panel. GTR Test ID Help Each Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version With this type of GSD, there is lack of the branching enzyme. This abnormal glycogen is thought to stimulate the immune system. The result is a great deal of scarring (cirrhosis) of the liver as well as other organs, such as muscle and heart. Causes of Glycogen Storage Disease. When glucose is changed into glycogen, a different enzyme is. Other Skeletal Spine: Disease onset < 21 years Lordosis (50%) Scoliosis (10% to 33%) Rigid spine Glycogen storage disease of heart, Lethal, Congenital Epidemiology: 8 patients Glycogen storage disease, Muscle, Type 0 (GSD0B) 2
Glycogen storage disorders mostly tend to affect your liver and muscles. However, some glycogen storage disorders can affect other parts of the body such as the kidney, heart, blood vessels, nervous system and bowel (see below). The different types of glycogen storage disorder include: Type Ia (von Gierke's disease), type Ib. Type II (Pompe's. Glycogen Storage Disease (GSD) is an extremely rare genetic metabolic disease that occurs in 1/100,000 births. There are several different types of GSD, and Sophie's type 1b (GSD1b) only occurs in 1/1,000,000 births. It is classified as a rare disease and we estimate about 500-800 people living with this disease At least that's how glycogen storage and breakdown normally work. But when someone has glycogen storage disease, one or more of these steps is disrupted — and this leads to problems with muscle, liver, heart, and other organ tissue. Types of Glycogen Storage Disease. Believe it or not, there are at least 16 types of GSD (type 0 through 15) McArdle disease is a rare muscle disorder. In this disease, the muscle cells can't break down a complex sugar called glycogen. It is part of a group of diseases called glycogen storage diseases. Another name for McArdle disease is glycogen storage disease type 5 (GSD 5 or GSD V). Your cells use a simple sugar, called glucose, for energy Diseases and Disorders, Diseases of Carbohydrate Metabolism, Glycogen Storage Diseases. Introduction to McArdle Disease Glycogen storage disease type 5 (GSD5) is an autosomal recessive disorder more commonly known as McArdle disease. This disease was originally described by Brian McArdle in 1951, hence the association of his name with the disease
E74.04 McArdle disease 0-20 1, 2E, 3 E74.09 Other glycogen storage disease 0-20 1, 2E, 3 E74.12 Hereditary fructose intolerance 0-20 1, 2E, 3 E74.19 Other disorders of fructose metabolism 0-20 1, 2E, 3 E74.21 Galactosemia 0-20 1, 2E, 3 E74.29 Other disorders of galactose metabolism 0-20 1, 2E, 3 E74. A rare inherited type of glycogen storage disease caused by deficiency of amylo-1,4-1,6 transglucosidase. An autosomal recessive glycogen storage disease in which there is deficient expression of 6-phosphofructose 1-kinase in muscle (phosphofructokinase-1, muscle type) resulting in abnormal deposition of glycogen in muscle tissue Lysosomal Storage Disease List. The scientific community has identified more than 40 types of lysosomal storage diseases, and that number keeps growing. Although the different types of LSDs are rare individually, taken together they affect roughly 1 in 7,700 births, making them a relatively common health problem
Type II Glycogen Storage Disease. Synonyms: Acid Maltase Deficiency (AMD), Pompe Disease. Glycogen Storage Diseases Handbook. Pompe disease (Type II GSD) is an autosomal recessive genetic disease that is caused by a lack of function of the enzyme acid alpha-1,4-glucosidase [also called acid maltase] for Glycogen Storage Disease Type I Glycogen Storage Disease Type I (GSDI) is a genetic metabolic disorder of the liver. GSD I causes the inability of the liver to breakdown glycogen to glucose which the body uses as its main source of fuel. Glycogen is a stored form of sugar in the body. As a result of the inability to breakdown glycogen. Glycogen storage disease (GSD) is an inherited metabolic disease caused by deficiency in various enzymes that are related to glycogenolysis and gluconeogenesis. The most common type, GSD Ia, is an autosomal recessive disorder that leads to abnormal glucose metabolism and glycogen accumulation induced by the defect of glucose-6-phosphatase. 1, 2. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia. J Inherit Metab Dis. 2019 May;42(3):470-479. doi: 10.1002/jimd.12069
The team applied MALDI TW IMS to analyze the brains of healthy mice and of two different mouse models of glycogen storage diseases: a model of Lafora disease and a model of glucose storage disease (GSD) type III. Sun commented, This new technique allows us to quantify the amount of these sugars with high accuracy while also maintaining the. 8 depositing this insoluble biopolymer in both organs is the same? One form of the polymer needs to be reused rapidly, while the other does not. Polymers of glucose have long been of interest as there are many glycogen storage diseases Glycogen storage disease due to muscle glycogen phosphorylase deficiency Disease definition Myophosphorylase deficiency (McArdle's disease), or glycogen storage disease type 5 (GSD5) , is a severe form of glycogen storage disease characterized by exercise intolerance
Pompe disease is also called GSD II, which stands for glycogen. Glycogen is the storage form of glucose. When the body does not need to use all of its available glucose, it stores it mainly in the liver and muscles as glycogen. Glycogen is made up of many connected molecules of glucose. storage disease type II. These mice recapitulate key features of glycogen storage disease type II (GSDII) and provide a model for studying the underlying mechanism of GSDII. Of note, C57BL/6NJ- Gaa tm1Jhng /J mice, available as Stock No. 034609 , also survive into adulthood, however they carry a mutation orthologous to one found in human IOPD making it much closer. ICD-9-CM 271.0 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 271.0 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes) So far, 11 distinct glycogen storage diseases and subforms have been identified. The typical symptoms and complications in addition to hepatomegaly include: hypoglycemia, nephromegaly, cirrhosis of the liver, and myasthenia. These are the most common types of glycogenoses: Gierke's disease (glycogen storage disease type 1
Prevention of hypertriglyceridemia is one of the biomedical targets in Glycogen Storage Disease type 1a (GSD Ia) patients, yet it is unclear how hypoglycemia links to plasma triglyceride (TG) levels. We analyzed whole‐body TG metabolism in normoglycemic (fed) and hypoglycemic (fasted) hepatocyte‐specific glucose‐6‐phosphatase deficient. Glycogen storage disease type IX is a metabolic disorder resulting from a deficiency of hepatic phosphorylase kinase, a hexadecameric enzyme comprising 4 copies each of 4 unique subunits encoded by 4 different genes: alpha (PHKA2), beta (PHKB; 172490), gamma (PHKG2; 172471), and delta (CALM1; 114180).Mutations within the PHKA2, PHKB, and PHKG2 genes result in GSD9A, GSD9B (), and GSD9C.
E74.09 Other glycogen storage disease. E74.1 Disorders of fructose metabolism. E74.10 Disorder of fructose metabolism, unspecified. E74.11 Essential fructosuria. E74.12 Hereditary fructose intolerance. Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes Glycogen Storage Disease Absence of glucose-6-phosphatase or other enzymes necessary for glycogen degradation, as occurs in a variety of glycogen storage diseases, would prevent the use of stored glycogen to maintain the blood glucose concentration in the fasting state Type a is the more frequent type, affecting about 80% of patients. Clinical description The disease may manifest at birth by enlarged liver or, more commonly, between the ages of three to four months by symptoms of fast-induced hypoglycemia (tremors, seizures, cyanosis, and apnea)
. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. Three transcript variants encoding the same protein have been found for this gene Glycogen storage disease type IV is an inherited abnormality of glucose metabolism that is seen in Norwegian Forest cats. It is inherited as a simple autosomal recessive trait and can manifest in two ways: By far the most common form is stillbirth or death within a few hours of birth. This probably results from the kittens having insufficient. Patients with Glycogen Storage Disease type 1a (GSD Ia) primarily present with life-threatening hypoglycemia and display severe liver disease characterized by hepatomegaly. Despite strict dietary management, long-term complications still occur, amongst which liver tumor development
Introduction. Type 1 glycogen storage disease (type 1‐GSD) is a rare inherited metabolic disease characterized by a glucose‐6 phosphatase deficiency , which is frequently complicated by renal stone disease.Urate stones have been considered the most common stone type, although calcium oxalate stones have also been described Glycogen Storage Disease Type II is the umbrella term under which the inherited and often fatal Pompe Disease falls. Pompe disease results from a lysosomal deficiency in acid alpha-glucosidase (GAA) so the body is unable to break down the complex sugar called glycogen. Glycogen is the storage form of sugar (aka glucose) Jerrod [last name withheld] has been living with the consequences of his rare and potentially deadly genetic liver disorder known as glycogen storage disease (GSD) Type Ia since birth and his. Lafora disease is a fatal autosomal recessive disease that is the result of a defect in glycogen metabolism. The disease gets its name from the Spanish neuropathologist, Gonzalo Rodriguez Lafora, who initially characterized the disorder. Lafora disease is characterized by the presence of inclusion bodies (the composition of which is glycogen.
Chen YT. Glycogen storage diseases. In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw Hill, New York 2001. Roscher A, Patel J, Hewson S, et al. The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada Glycogen storage disease (GSD) type Ib is a rare inherited disorder of carbohydrate metabolism. It results from a deficiency in the glucose-6-phosphate transport system in the microsomes .Patients typically have symptoms similar to those with the more common GSD type Ia, i.e., hypoglycemia, lactic acidosis, adiposity, hepatomegaly, and growth retardation Muscle disease, any of the diseases and disorders that affect the human muscle system. Because muscles and neurons supplying muscle cells operate as functional units, disease of both systems can result in muscular atrophy and paralysis. Learn about the types, causes, and treatment of muscle disease glycogen storage disease. n. Any of various genetic diseases caused by deficiency of one of the enzymes involved in breaking down or synthesizing glycogen, resulting in storage of abnormal amounts or types of glycogen and often affecting the liver, muscles, or both. Also called glycogenosis
Branching enzyme deficiency (type IV glycogenosis, Andersen's disease) is characterized by liver disease and progressive cirrhosis; the myopathy is a minor component of the disease. Branching enzyme attaches short glucosyl chains with α-1,6-glucosyl bonds to glycogen to start new chains that are subsequently lengthened by glycogen synthetase CLINICAL FEATURES OF GLYCOGEN STORAGE DISEASE Type 0. Glycogen storage disease type 0 is secondary to a lack of glycogen synthethase activity, which causes a marked decrease in liver glycogen content. It is not a true GSD. Its gene locus is at 12p12.2, and it is inherited as autosomal recessive 3.1. Glycogen Storage Diseases (III and V) Glycogen storage disease type III (GSD III) is an autosomal recessive disease caused by the deficiency of the glycogen debranching enzyme, encoded by the AGL gene. It is characterized by variable liver, cardiac muscle, and skeletal muscle involvement
Niemann-Pick disease type C, or NPC, is a rare genetically inherited condition caused by mutations in either the NPC1 or NPC2 genes.. These mutations impair intracellular transport of cholesterol and other molecules, which causes progressive neurologic and developmental problems.. Now, cholesterol reaches the cells packed in lipoproteins, which bind to low density lipoprotein, or LDL. Test description. The Invitae Hereditary Rhabdomyolysis Panel analyzes genes that are associated with rhabdomyolysis and related hereditary conditions involving features of rhabdomyolysis. The genetic heterogeneity associated with these conditions can make it difficult to use phenotype as the sole criterion to select a definitive cause Pompe disease is a rare (estimated at 1 in every 40,000 births) inherited and often fatal disorder that disables the heart and muscles. It is caused by mutations in a gene that makes an enzyme called alpha-glucosidase (GAA). Normally, the body uses GAA to break down glycogen, a stored form of sugar used for energy GSD is caused by a defect in an enzyme gene or a transporter gene involved in glycogen metabolism; types I, VII, and XI for processing of glucose, types II-VI and IX for processing of glycogen, and type 0 for glycogen synthesis. Pompe disease (type II) is a lysosomal storage disease. Category. Congenital disorder of metabolism
Glycogen storage diseases are carbohydrate metabolism disorders.There are many numbered and named types, all of which are caused by deficiencies of enzymes involved in glycogen synthesis or breakdown; the deficiencies may occur in the liver or muscles and cause hypoglycemia or deposition of abnormal amounts or types of glycogen (or its intermediate metabolites) in tissues . Cori disease is a type of glycogen storage disorder (type III) caused by a deficiency in the glycogen debrancher enzyme (α-1,6-glucosidase). McArdle disease is a glycogen storage disease characterized by a deficiency in glycogen phosphorylase in skeletal muscles Glycogen storage disease (GSD) type Ib is caused by the deficiency of glucose-6-phosphate translocase activity. The elder brother of the proband died at age 20 months, and GSD Ia, a disease caused by the deficiency of glucose-6-phosphatase, was the diagnosis As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other. Trial or other data Oct 16 · Sanofi initiates the PIII COMET study of GZ 402666 in patients with glycogen storage disease (Pompe disease) type II (NCT02782741). The study will evaluate the efficacy and safety of repeated biweekly IV infusions of GZ 402666 (20 mg/kg) in comparison with alglucosidase alfa in treatment-naïve patients with late.
Generalized RDEB, severe form. Generalized UDP-galactose-4-epimerase deficiency. Generalized uridine diphosphate galactose-4-epimerase deficiency. Genetic 46,XX disorder of sex development. Genetic 46,XX DSD. Genetic 46,XY disorder of sex development. Genetic 46,XY disorder of sex development of endocrine origin Jonah has a rare form of glycogen storage disease, a hereditary disorder that means his liver can store sugar but can't release it, causing him to have dangerously low blood sugar levels that can. Long-term effects of cornstarch (CS) therapy on biochemical values and physical growth in children with type I glycogen storage disease (GSD I) were compared to those of children receiving continuous nocturnal nasogastric glucose feedings (CNG). Only patients who had received more than 5 years of dietary therapy (either CS or CNG) were evaluated. Six patients (five female, age 13.5 years±1.3. Different forms of acid alpha-glucosidase are obtained by proteolytic processing. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. Three transcript variants encoding the same protein have been found for this gene
At present, Pompe disease stands for the very broad clinical spectrum of glycogen storage disease type II (GSDII) including infantile, childhood, and adult variants. The name acid maltase deficiency (AMD) is also used . Type I glycogen storage disease (GSD I), also known as von Gierke's disease, is the most common form of glycogen storage disease, accounting for 25% of all cases. It is an inherited disorder that affects the metabolism - the way the body breaks food down into energy. After we eat, excess glucose is stored in the liver as. Search Tests: (Search by disease, test name, gene name, test code, or keyword. (MAC) or other payer being billed, as requirements may differ. CPT coding is the sole responsibility of the billing party. Glycogen Storage Disease Type 0, Liver Isoform (GYS2) Glycogen Storage Disease Type 0, Muscle Isoform (GYS1 GSD 1a is a type of glycogen storage disease marked by the body's inability to metabolize glycogen into glucose, resulting in hypoglycemia, high levels of fat in the blood, and impaired.
Glycogen storage diseases are rare genetic disorders of glycogen synthesis, degradation, or metabolism regulation. When these patients are subjected to anesthesia, perioperative complications can develop, including hypoglycemia, rhabdomyolysis, myoglobinuria, acute renal failure, and postoperative fatigue. The objective of this study was to describe the perioperative course of a cohort of. treating glycogen storage disease type II (GSD-II or Pompe diseaseusing enzyme replacement therapy) . '712 patent col. 2 ll. 4550. Pompe disease- is a genetic disorder affecting muscles caused by a deficiency of acid α-glucosidase (GAA), a lysosomal enzyme that breaks down glycogen Glycogen Content And Structure Liver Muscle 82657 GSD Type Ia (Von Gierke)* - Glucose-6-Phosphatase Liver 82657 GSD Type II (Pompe disease, acid maltase deficiency)* - Acid alpha-Glucosidase - See also the Lysosomal Storage Disease Test Request Form - Please provide clinical details by completing th
R-HSA-3322077, Glycogen synthesis R-HSA-3858516, Glycogen storage disease type 0 (liver GYS2) R-HSA-3878781, Glycogen storage disease type IV (GBE1) SIGNOR i: Expressed in liver and 80 other tissues: Genevisible i: P54840, HS: Family and domain databases. Entry name i:. The findings, which show a direct connection between abnormal glycogen storage and defective protein function in the brain, have implications for many other GSDs and congenital disorders of. 1) Our work on Lafora disease and other aspects of brain metabolism is funded by an 8-year $8.8M grant from the National Institute of Neurological Disorders and Stroke (NINDS) that runs from 2020-2028. The project number of our work is R35116824 and titled, Brain Glycogen - Metabolism, Mechanisms, and Therapeutic Potential. 2) A $9.3m NINDS P01 (NS097197) program project grant funds are. Introduction. Glycogen storage disease type IV (GSD IV, Andersen disease, amylopectinosis, OMIM:232500) is an autosomal recessive disorder of glycogen metabolism ().GSD IV is estimated to occur in 1 in 600 000 to 800 000 individuals worldwide ().GSD IV is caused by deficiency of glycogen-branching enzyme (GBE), encoded by GBE1 gene, leading to accumulation of amylopectin-like glycogen.